Skip to content

Screening of Patients Admitted to a Local Hospital With Pocket-sized Ultrasound

Screening With Pocket-sized Ultrasound of Patients Admitted to Department of Medicine at a Local Hospital

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01081210
Enrollment
400
Registered
2010-03-05
Start date
2010-03-31
Completion date
2010-10-31
Last updated
2021-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Disease, Dyspnea, Heart Disease, Kidney Disease, Liver Disease

Keywords

Echocardiography, Heart failure, Kidney, Lung, Aorta

Brief summary

Ultrasound (US) is widely used as a diagnostic tool in a hospital setting. In a medical department, diagnosis like heart failure or most kinds of heart diseases, hypervolemia, hypovolemia, pleural effusion, pericardial effusion, ascites, diseases in the gall bladder/bile tract, urine tract and venous thrombosis are common. US is the key diagnostic tool in these diagnosis, and on early diagnosis is crucial both on behalf of the patients well-being, and for hospital logistic reasons. 1. The aim is to study the clinical use of pocket sized US as a screening diagnostic tool in an department of internal medicine. Method: All patients admitted (in certain preset periods) to Department of medicine will be screened with pocket sized US by expert user. Changes in diagnoses, as well as medications as a result of US screening will be the endpoints. US findings will be validated against standard echocardiography, or standard US/CT/MRI performed at the Radiological department. 2. The aim is to study the clinical use of pocket sized US as a screening diagnostic tool in a department of cardiology. Method: All patients admitted (in certain preset periods) to Department of cardiology will be screened with pocket sized US for heart disease, pericardial and pleural effusion. Examinations by expert users. Specific findings could be myocardial dysfunction as heart failure, cardiomyopathies, regional dysfunction due to ischemia, valvular dysfunction, atrial enlargement, and pleural/pericardial effusion. Changes in diagnoses, as well as medications as a result of US screening will be the endpoints. US findings will be validated against standard echocardiography in all. 3. As in 1), but examination by non-expert users compared to expert users.

Interventions

OTHERUltrasound examination

Screening with bedside ultrasound examination

Sponsors

Norwegian University of Science and Technology
CollaboratorOTHER
Helse Nord-Trøndelag HF
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

* Patients admitted to Dep. of Medicine at Levanger Hospital

Exclusion criteria

* Not able to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic sensitivity and specificityAfter 3-6 monthsDiagnostic accuracy and clinical usefulness of ultrasound screening as add on examination. Change in working diagnosis after ultrasound examination will be tested, and gold standards (echocardiography and examinations at Department of radiology) will be used for testing of sensitivity and specificity.

Secondary

MeasureTime frameDescription
Non-expertsAfter 3-6 monthsValidation of results from ultrasound examination made by non-experts compared to expert users.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026